Table 1.
List of registered clinical trials on the use of mesenchymal stromal cell-derived extracellular vesicles for tissue injury
|
Tissue injury disease
|
Condition
|
Treatment
|
Trial ID
|
Status
|
| Chronic lung disease | Pediatric bronchopulmonary dysplasia | BM-MSC-derived EVs | NCT03857841 | Phase I |
| Lung disease | Pneumonia, COVID-19 | BM-MSC-derived EVs | NCT04493242 | Not yet recruiting |
| Lung disease | Pneumonia, COVID-19 | Inhalation of mesenchymal stem cell exosomes | NCT04276987 | Phase I |
| Multiple organ failure | Multiple organ dysfunction syndrome | MSC exosomes | NCT04356300 | Not yet recruiting |
| Lung disease | Pulmonary infection | MSC exosomes | NCT04544215 | Recruiting |
| Dry eye | GVHD | UC-MSC exosomes | NCT04213248 | Recruiting |
| Cartilage injury | Osteoarthritis | Secretome or EVs from adipose MSCs | NCT04223622 | Not yet recruiting |
| Skin disease | Dystrophic epidermolysis bullosa | BM-MSC EVs | NCT04173650 | Phase II |
| Brain | Cerebrovascular disorders | Allogenic MSCs enriched with miR-124 | NCT03384433 | Phase II |
BM: Bone marrow; COVID-19: Coronavirus disease 2019; EV: Extracellular vesicle; GVHD: Graft-vs-host disease; MSC: Mesenchymal stromal cell; UC: Umbilical cord.